DeCure for MPI-congenital disorder of glycosylation
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for MPI-congenital disorder of glycosylation — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMPI-congenital disorder of glycosylation maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for mpi-congenital disorder of glycosylation is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Despite advances in identifying and diagnosing congenital disorders of glycosylation, treatment options remain limited and are often constrained to managing symptoms rather than addressing the underlying cause. A 2021 review and a 2024 overview both state that available therapies are mostly limited to symptomatic management of disease manifestations. The 2024 overview notes that recent years have brought remarkable advances in treatment approaches for some CDG, with innovative therapies targeting both the root cause and resulting manifestations transitioning from research to practical application. However, neither abstract provides concrete numbers on survival, response rates, or sample sizes for any specific therapy.
The 2008 review describes CDG as a rapidly growing group of inherited errors of metabolism, with over 30 subtypes identified at a molecular and biochemical level at that time. Clinical manifestations are heterogeneous and may be highly variable within the same subtype and even among affected siblings. The 2005 report describes a patient with CDG type Ia, the most common form, emphasising cutaneous findings including the hanging fat sign, but provides no treatment data. The 2017 review notes that symptoms can be evident as early as the prenatal period and that biochemical screening and confirmatory molecular genetic tests are available, though their sensitivity is imperfect and some patients are now diagnosed by whole exome sequencing. It states that early diagnosis is important because treatment options are available for some subtypes, but again gives no numbers.
The abstracts are consistent in stating that treatment options are limited and mostly symptomatic, while also claiming recent progress for some subtypes. No abstract provides evidence of efficacy for any specific drug, reports response rates, or gives survival data. What is still missing are published clinical trial results with measurable outcomes, adequate funding for trials in these ultra-rare diseases, and reliable patient stratification to identify which subtypes might respond to which emerging therapies.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Frontiers in Genetics · 2021 · 41 citations · open access
Treatment Options in Congenital Disorders of Glycosylation
AbstractDespite advances in the identification and diagnosis of congenital disorders of glycosylation (CDG), treatment options remain limited and are often constrained to symptomatic management of disease manifestations. However, recent years have seen significant advances in treatment and novel therapies aimed both at the causative defect and secondary disease manifestations have been transferred from bench to bedside. In this review, we aim to give a detailed overview of the available therapies and rising concepts to treat these ultra-rare diseases.
Journal of Inherited Metabolic Disease · 2008 · 21 citations
Congenital disorders of glycosylation—a challenging group of IEMs
AbstractCongenital disorders of glycosylation (CDG) are a rapidly growing group of inherited errors of metabolism (IEMs) due to an impairment of one or several glycosylation pathways. During recent years over 30 CDG subtypes have been identified at a molecular and biochemical level. The clinical manifestations in CDG are heterogeneous and may be highly variable within the same subtype and even among affected siblings. Novel insights into the extremely complex glycosylation pathways have necessitated several reclassifications of the group of CDG. Today CDG comprise not only the formerly known multisystem glycosylation defects but also some tissue-specific glycosylation defects, implicating a different diagnostic work-up depending on the underlying glycosylation defect. In 2007 the expanding group of CDG is an enormous challenge to all specialists working in the field of IEMs. This review gives a brief overview about the expanded group of CDG and summarizes the main implications for clinicians.
Clinical Case Reports · 2018 · 13 citations · open access
A novel homozygous mutation in the mannose phosphate isomerase gene causing congenital disorder of glycation and hyperinsulinemic hypoglycemia in an infant
AbstractWe report a 4 years girl with congenital disorders of glycosylation (CDG) type Ib due to a novel homozygous mutation in MPI gene. She presented with diazoxide-responsive hyperinsulinemic hypoglycemia. CDG should be considered in unexplained hypoglycemia particularly in consanguineous families. Diagnosis enables monitoring/prevention of disease comorbidities and early effective treatment.
Molecular Genetics and Metabolism · 2024 · 12 citations · open access
Treatment of congenital disorders of glycosylation: An overview
AbstractWhile the identification and diagnosis of congenital disorders of glycosylation (CDG) have rapidly progressed, the available treatment options are still quite limited. Mostly, we are only able to manage the disease symptoms rather than to address the underlying cause. However, recent years have brought about remarkable advances in treatment approaches for some CDG. Innovative therapies, targeting both the root cause and resulting manifestations, have transitioned from the research stage to practical application. The present paper aims to provide a detailed overview of these exciting developments and the rising concepts that are used to treat these ultra-rare diseases.
Cutaneous Findings in Congenital Disorders of Glycosylation: The Hanging Fat Sign
AbstractThe congenital disorders of glycosylation are a group of rare metabolic disorders with predominantly neurologic findings. Some variants of this disorder also exhibit cutaneous manifestations. We report a patient with a congenital disorder of glycosylation type Ia, the most common form, with emphasis on the cutaneous findings of this type, and summarize the cutaneous findings in the other forms of the disorder.
Neonatal Presentations of Congenital Disorders of Glycosylation
AbstractCongenital disorders of glycosylation (CDG) are a variable, rapidly expanding group of genetic metabolic disorders. Glycosylation is fundamental to the processing of proteins and lipids, and as such, disorders in these pathways can cause multisystemic effects. Symptoms can be evident as early as the prenatal period and should be suspected in an infant with multisystemic disease. Biochemical screening and confirmatory molecular genetic tests are available; however, their sensitivity is imperfect and some patients are now being diagnosed by whole exome sequencing. Early diagnosis is important, because treatment options are available for some subtypes.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
